中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
10期
790-792
,共3页
癌,肝细胞%复发%索拉非尼%微波消融%栓塞,治疗性%治疗效果
癌,肝細胞%複髮%索拉非尼%微波消融%栓塞,治療性%治療效果
암,간세포%복발%색랍비니%미파소융%전새,치료성%치료효과
Carcinoma,hepatocellular%Recurrence%Sorafenib%Microwave therapentic%Embolization,therapeutic%Treatment outcome
目的 探讨索拉非尼联合微波消融(MCT)和经皮肝动脉捅管化疗栓塞(TACE)治疗复发性肝细胞癌患者的疗效.方法 收集90例行MCT和TACE治疗的复发性肝细胞癌患者,其中42例采用索拉非尼+ MCT+ TACE治疗(治疗组),48例行MCT+ TACE治疗(对照组),分析其疗效、生存状况和不良反应.结果 治疗组患者的有效率为66.7％,与对照组(52.0％)比较,差异无统计学意义(P＞0.05).治疗组患者的疾病控制率为83.3％,高于对照组(64.5％,P＜0.05).治疗组患者的生存时间为6 ～28个月,中位生存时间为18.5个月;对照组患者的生存时间为5～22个月,中位生存时间为10.3个月.治疗组患者的中位生存时间高于对照组,差异有统计学意义(P＜0.05).治疗组患者腹泻、手足综合征、皮疹的发生率均高于对照组,差异均有统计学意义(均P＜0.05);两组患者疲劳、消化道反应、骨髓抑制、肝功能异常的发生率,差异均无统计学意义(均P ＞0.05).结论 索拉非尼联合MCT和TACE治疗能改善复发性肝细胞癌患者的疾病控制率,提高生存率.
目的 探討索拉非尼聯閤微波消融(MCT)和經皮肝動脈捅管化療栓塞(TACE)治療複髮性肝細胞癌患者的療效.方法 收集90例行MCT和TACE治療的複髮性肝細胞癌患者,其中42例採用索拉非尼+ MCT+ TACE治療(治療組),48例行MCT+ TACE治療(對照組),分析其療效、生存狀況和不良反應.結果 治療組患者的有效率為66.7％,與對照組(52.0％)比較,差異無統計學意義(P＞0.05).治療組患者的疾病控製率為83.3％,高于對照組(64.5％,P＜0.05).治療組患者的生存時間為6 ～28箇月,中位生存時間為18.5箇月;對照組患者的生存時間為5～22箇月,中位生存時間為10.3箇月.治療組患者的中位生存時間高于對照組,差異有統計學意義(P＜0.05).治療組患者腹瀉、手足綜閤徵、皮疹的髮生率均高于對照組,差異均有統計學意義(均P＜0.05);兩組患者疲勞、消化道反應、骨髓抑製、肝功能異常的髮生率,差異均無統計學意義(均P ＞0.05).結論 索拉非尼聯閤MCT和TACE治療能改善複髮性肝細胞癌患者的疾病控製率,提高生存率.
목적 탐토색랍비니연합미파소융(MCT)화경피간동맥통관화료전새(TACE)치료복발성간세포암환자적료효.방법 수집90례행MCT화TACE치료적복발성간세포암환자,기중42례채용색랍비니+ MCT+ TACE치료(치료조),48례행MCT+ TACE치료(대조조),분석기료효、생존상황화불량반응.결과 치료조환자적유효솔위66.7％,여대조조(52.0％)비교,차이무통계학의의(P＞0.05).치료조환자적질병공제솔위83.3％,고우대조조(64.5％,P＜0.05).치료조환자적생존시간위6 ～28개월,중위생존시간위18.5개월;대조조환자적생존시간위5～22개월,중위생존시간위10.3개월.치료조환자적중위생존시간고우대조조,차이유통계학의의(P＜0.05).치료조환자복사、수족종합정、피진적발생솔균고우대조조,차이균유통계학의의(균P＜0.05);량조환자피로、소화도반응、골수억제、간공능이상적발생솔,차이균무통계학의의(균P ＞0.05).결론 색랍비니연합MCT화TACE치료능개선복발성간세포암환자적질병공제솔,제고생존솔.
Objective To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer.Methods From January 2006 to January 2010,90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital.The treatment group received sorafenib + MCT + TACE,and the control group received MCT + TACE.Results RR of the treatment group was 66.7％,which of the control group was 52.0％ (P ＞0.05).DCR was 83.3％ in the treatment group and 64.5％ in the control group (P ＜0.05).Through a comparison of survival curves along with the extension of time,the survival rates of the two groups were decreased,but the treatment group (group 1) had a significantly higher one than the control group (group 2),with a statistically significant difference (P ＜ 0.05).Conclusion Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC.
